Guggenheim Maintains Buy on MBX Biosciences, Lowers Price Target to $77
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and lowers the price target from $84 to $77.
Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and lowers the price target from $84 to $77.